Previous 10 | Next 10 |
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement PR Newswire DUBLIN , Oct. 31 , 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural ...
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Stakeholder Engagement We recognize that our stakeholders - including employees, healthcare providers, patients, caregivers, investors, policy makers,...
2023-10-25 16:28:08 ET Alkermes plc (ALKS) Q3 2023 Results Earnings Conference Call October 25, 2023, 08:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Iain Brown - Senior Vice President and Chief Financi...
2023-10-25 07:05:53 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Evercore ISI upgrades Alkermes to outperform, cites orexin potential Alkermes Q3 2023 Earnings Preview Seeking Alp...
St. Joe Company (The) (JOE) is expected to report for Q1 2024 Meta Platforms Inc. (META) is expected to report $3.62 for Q3 2023 Industrial Logistics Properties Trust (ILPT) is expected to report $0.11 for Q3 2023 Mid-America Apartment Communities Inc. (MAA) is expected to report $2.2...
Alkermes plc Reports Third Quarter 2023 Financial Results PR Newswire — Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and N...
Alkermes plc (ALKS) is expected to report $0.31 for Q3 2023
2023-10-24 14:15:19 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes Q3 2023 Earnings Preview Alkermes to grant Te...
2023-10-24 12:11:07 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes to grant Teva license for generic Vivitrol, settles l...
NORTHAMPTON, MA / ACCESSWIRE / October 23, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Alkermes' mission is to research, develop and commercialize important new medicines for patients suffering from complex medical conditions, including those...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...